東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The single market and pharmaceutical...

Timur, Aysegul.

FindBook

Google Book

Amazon

博客來

The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence?

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence?/
作者:	Timur, Aysegul.
面頁冊數:	166 p.
附註:	Source: Dissertation Abstracts International, Volume: 68-04, Section: A, page: 1579.
Contained By:	Dissertation Abstracts International68-04A.
標題:	Economics, General. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3260097

The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence?
Timur, Aysegul.

The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence? - 166 p.

Source: Dissertation Abstracts International, Volume: 68-04, Section: A, page: 1579.

Thesis (Ph.D.)--University of South Florida, 2007.

During the last two decades, the European Union (EU) has experienced closer market integration through the removal of trade barriers, the establishment of a single market, and the reduction of exchange rate volatility. In addition, there have been several structural reforms in product markets designed to increase competition, monitor crosscountry price differences and increase transparency. One anticipated effect of market integration is price convergence, because of the reduced potential for price discrimination across the EU. This dissertation explores market integration and price convergence in the European pharmaceutical market, which is the fifth largest industry in the EU. Since 1985, many EU directives have been adopted to achieve a single EU-wide pharmaceutical market, with the aim of enhancing the quality of life for European citizens and the European pharmaceutical industry's competitiveness and research and development capability. Using annual 1994--2003 data from five EU countries on prices of drugs used to treat cardiovascular disease, this dissertation explains how the integration process has affected cross-country drug price dispersion in the EU. The results show strong evidence of price convergence in the pharmaceutical market, with long term price differences arising from country fixed effects.Subjects--Topical Terms:

1017424
Economics, General.

The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence?
LDR:02229nmm 2200265 4500 001 1835770
005 20071226141954.5
008 130610s2007 eng d
035 $a (UMI)AAI3260097
035 $a AAI3260097
040 $a UMI $c UMI
100 1 $a Timur, Aysegul. $3 1924393
245 1 4 $a The single market and pharmaceutical industry in the European Union: Is there any evidence of price convergence?
300 $a 166 p.
500 $a Source: Dissertation Abstracts International, Volume: 68-04, Section: A, page: 1579.
500 $a Adviser: Gabriel Picone.
502 $a Thesis (Ph.D.)--University of South Florida, 2007.
520 $a During the last two decades, the European Union (EU) has experienced closer market integration through the removal of trade barriers, the establishment of a single market, and the reduction of exchange rate volatility. In addition, there have been several structural reforms in product markets designed to increase competition, monitor crosscountry price differences and increase transparency. One anticipated effect of market integration is price convergence, because of the reduced potential for price discrimination across the EU. This dissertation explores market integration and price convergence in the European pharmaceutical market, which is the fifth largest industry in the EU. Since 1985, many EU directives have been adopted to achieve a single EU-wide pharmaceutical market, with the aim of enhancing the quality of life for European citizens and the European pharmaceutical industry's competitiveness and research and development capability. Using annual 1994--2003 data from five EU countries on prices of drugs used to treat cardiovascular disease, this dissertation explains how the integration process has affected cross-country drug price dispersion in the EU. The results show strong evidence of price convergence in the pharmaceutical market, with long term price differences arising from country fixed effects.
590 $a School code: 0206.
650 4 $a Economics, General. $3 1017424
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0501
690 $a 0572
710 2 0 $a University of South Florida. $3 1020446
773 0 $t Dissertation Abstracts International $g 68-04A.
790 1 0 $a Picone, Gabriel, $e advisor
790 $a 0206
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3260097